Latest News
BlueRock Therapeutics reports sustained safety and efficacy of bemdaneprocel in Parkinson's disease trial
7 October 2025 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) and its subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, on Tuesday reported positive 36-month data from a Phase I clinical tr...
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
7 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of Verona Pharma plc (Nasdaq:VRNA).Verona is now a wholly owned subsidiary of...
MaaT Pharma receives positive safety update for Phase 2b PHOEBUS trial of MaaT033
7 October 2025 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) announced on Tuesday that the independent Data Safety Monitoring Board (DSMB) has completed its second planned safety interim analysis of the Phase 2b PHOEBUS tri...
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
7 October 2025 - Contract development and manufacturing organisation (CDMO) Oxford Biomedica plc (OXB) (LON:OXB) on Tuesday announced the acquisition of a commercial-scale, FDA-approved viral vector manufacturing facility in Durham, North Carolina, f...
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
7 October 2025 - Renew Biotechnologies subsidiary Wasatch BioLabs (WBL), a US sequencing service provider focused on long-read sequencing, announced on Monday the addition of three Oxford Nanopore-developed research-use-only (RUO) assays to its servi...